Journal
JOURNAL OF THE IRANIAN CHEMICAL SOCIETY
Volume 18, Issue 10, Pages 2517-2534Publisher
SPRINGER
DOI: 10.1007/s13738-021-02212-0
Keywords
Phytocannabinoid; Delta(9)-Tetrahydrocannabinol; Cannabidiol; SARS-CoV2; Covid-19; Dronabinol; Epidiolex
Categories
Funding
- Iran National Science Foundation: INSF
- University of Zanjan
Ask authors/readers for more resources
Delta(9)-THC and CBD from Cannabis are important compounds with various pharmacological activities for treating different diseases. Effective identification of candidate drugs for Covid-19 is crucial, and these compounds have immunomodulatory and anti-inflammatory effects.
The very important psychoactive phytocannabinoid from Cannabis Delta(9) tetrahydrocannabinol (Delta(9)-THC) and its non-psychotropic member is cannabidiol (CBD). These compounds have a variety of pharmacological activities. THC has been approved for the treatment of nausea caused by chemotherapy, multiple sclerosis and chronic and neuropathic pain and research is underway to use it to treat stimulation of dementia, anorexia nervous and Tourette's syndrome. CBD has therapeutic benefits in Epilepsy, neuroprotective, cancer, inflammatory and anxiety. Recognizing candidate drugs efficiently in the new SARS-CoV2 disease 2019 (Covid-19) is crucial. Cannabidiol and Delta(9)-tetrahydrocannabinol have immunomodulatory and anti-inflammatory effects. They can reduce the uncontrolled cytokine production of acute lung injury. Although THD and CBD can be extracted from natural sources due to the disadvantages of this method such as difficulty in purification, cultivation, etc. It has been proven that chemical-synthesis methods of these two compounds can solve these problems. This review briefly summarizes the chemical-synthetic strategies of Dronabinol and Epidiolex from THC and CBD. [GRAPHICS] .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available